About

Home

Introduction

Statistics

Programs

Dignet

Gene

GenePair

BioSummarAI

Help & Docs

Documents

Help

FAQs

Links

Acknowledge

Disclaimer

Contact Us

Gene Information

Gene symbol: SMAD4

Gene name: SMAD family member 4

HGNC ID: 6770

Synonyms: DPC4

Related Genes

#	Gene Symbol	Number of hits
1	CD8A	1 hits
2	KRAS	1 hits
3	TP53	1 hits

Related Sentences

#	PMID	Sentence
1	25637015	Smad4 promotes differentiation of effector and circulating memory CD8 T cells but is dispensable for tissue-resident memory CD8 T cells.
2	25637015	In contrast, circulating memory CD8 T cells have no requirement for TGF-β but show signs of arrested development in the absence of Smad4, including aberrant CD103 expression.
3	25637015	Our data show that Smad4 is required for normal differentiation of multiple subsets of virus-specific CD8 T cells.
4	25637015	Smad4 promotes differentiation of effector and circulating memory CD8 T cells but is dispensable for tissue-resident memory CD8 T cells.
5	25637015	In contrast, circulating memory CD8 T cells have no requirement for TGF-β but show signs of arrested development in the absence of Smad4, including aberrant CD103 expression.
6	25637015	Our data show that Smad4 is required for normal differentiation of multiple subsets of virus-specific CD8 T cells.
7	25637015	Smad4 promotes differentiation of effector and circulating memory CD8 T cells but is dispensable for tissue-resident memory CD8 T cells.
8	25637015	In contrast, circulating memory CD8 T cells have no requirement for TGF-β but show signs of arrested development in the absence of Smad4, including aberrant CD103 expression.
9	25637015	Our data show that Smad4 is required for normal differentiation of multiple subsets of virus-specific CD8 T cells.
10	26185420	Pancreatic adenocarcinoma is characterized by several germline or acquired genetic mutations, the most common being KRAS (90%), CDK2NA (90%), TP53 (75%-90%), DPC4/SMAD4 (50%).
11	26185420	Recent reports note activity with immunotherapies such as CD40 agonists, CCR2 inhibitors, cancer vaccines, and novel combinations against the immunosuppressive tumor milieu are ongoing.